A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects with Psoriatic Arthritis.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Bimekizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Acronyms BE ACTIVE 2
- Sponsors UCB Biopharma
- 25 Jul 2018 Planned End Date changed from 1 Feb 2021 to 1 Nov 2020.
- 25 Jul 2018 Planned primary completion date changed from 1 Feb 2021 to 1 Nov 2020.
- 25 Jul 2018 Status changed from recruiting to active, no longer recruiting.